Volume 12, Issue 2 (Vol.12 No.2 Jul 2023)                   rbmb.net 2023, 12(2): 277-283 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ahmadzadeh A, Khodayar M J, Salehcheh M, Nazari Khorasgani Z, Matin M. Evaluation of the Total Oxidant Status to the Antioxidant Capacity Ratio as a Valuable Biomarker in Breast Cancer Patients. rbmb.net 2023; 12 (2) :277-283
URL: http://rbmb.net/article-1-1190-en.html
Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran & Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract:   (998 Views)
Background: The oxidative balance is a state of equilibrium between oxidants and antioxidants disrupted in various disorders, including BC. This study aimed to assess this equilibrium in breast cancer (BC) patients by looking at the oxidant-to-antioxidant ratio.

Methods: This case-control study comprised 40 women patients with breast cancer and 30 age-matched healthy individuals. The oxidation-reduction colorimetric technique was used to determine serum levels of total oxidant status (TOS) and total antioxidant capacity (TAC). The oxidant-to-antioxidant balance was estimated using the TOS- to- TAC ratio (TOS/TAC).

Results: The mean TOS in healthy individuals was 8.40±2.06 µmol/L, while in BC patients it was 13.31±2.16 µmol/L (P< 0.001). The mean serum level of TAC was 1.43±0.21 mmol/L in healthy individuals and 1.19±0.15 mmol/L in BC patients (P< 0.001). The mean serum TOS/TAC was 6.01±0.32 in the healthy individuals and 11.42±0.41 in the BC patients (P< 0.0001). There were direct correlations between TAC and estrogen receptor (r=0.339, P=0.038). The TOS/TAC level has a sensitivity of 100% and specificity of 83.33%, distinguishing patients with BC from healthy controls (P< 0.001). A significant trend of increasing risk with rising TOS/TAC levels was also seen [OR=3.62, (95 % CI 1.79, 7.35)].

Conclusions: In breast cancer, the serum TOS to TAC ratio can better diagnose oxidative equilibrium than either component alone.
Full-Text [PDF 471 kb]   (517 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2023/06/9 | Accepted: 2023/09/15 | Published: 2023/12/20

References
1. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1(2):182-8. [DOI:10.1602/neurorx.1.2.182] [PMID] []
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. [DOI:10.3322/caac.21763] [PMID]
3. Organization WH. Breast cancer now most common form of cancer 2021. Available from: https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action.
4. Hagag S, Kodous A, Shaaban HA. Molecular and Immunohistochemical Alterations in Breast Cancer Patients in Upper Egypt. Rep Biochem Mol Biol. 2023;11(4):532-46. [DOI:10.52547/rbmb.11.4.532] [PMID] []
5. Toyokuni S. Oxidative stress as an iceberg in carcinogenesis and cancer biology. Arch Biochem Biophys. 2016;595:46-9. [DOI:10.1016/j.abb.2015.11.025] [PMID]
6. Prasad S, Gupta SC, Pandey MK, Tyagi AK, Deb L. Oxidative Stress and Cancer: Advances and Challenges. Oxid Med Cell Longev. 2016;2016:5010423. [DOI:10.1155/2016/5010423] [PMID] []
7. Pilco-Ferreto N, Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016;49(2):753-62. [DOI:10.3892/ijo.2016.3558] [PMID]
8. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-11. [DOI:10.1016/j.clinbiochem.2005.08.008] [PMID]
9. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277-85. [DOI:10.1016/j.clinbiochem.2003.11.015] [PMID]
10. Wu R, Feng J, Yang Y, Dai C, Lu A, Li J, et al. Significance of serum total oxidant/antioxidant status in patients with colorectal cancer. PLoS One. 2017;12(1):e0170003. [DOI:10.1371/journal.pone.0170003] [PMID] []
11. Mahmood IH, Abdullah KS, Abdullah MS. Total antioxidant status in women with breast cancer.Pak J Med Sci. 2009;25(4):609-12.
12. Hammer C, Fanning A, Crowe J. Overview of breast cancer staging and surgical treatment options. Cleve Clin J Med. 2008;75 Suppl 1:S10-6. [DOI:10.3949/ccjm.75.Suppl_1.S10] [PMID]
13. El-Deeb MMK, El-Sheredy HG, Mohammed AF. The role of serum trace elements and oxidative stress in egyptian breast cancer patients. Adv Breast Cancer Res. 2016;5(1):37-47. [DOI:10.4236/abcr.2016.51004]
14. Feng JF, Lu L, Zeng P, Yang YH, Luo J, Yang YW, Wang D. Serum total oxidant/antioxidant status and trace element levels in breast cancer patients. Int J Clin Oncol. 2012;17(6):575-83. [DOI:10.1007/s10147-011-0327-y] [PMID]
15. Sener DE, Gönenç A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct. 2007;25(4):377-82. [DOI:10.1002/cbf.1308] [PMID]
16. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 2001;34(1):71-6. [DOI:10.1016/S0009-9120(00)00200-9] [PMID]
17. Sadati Zarrini A, Moslemi D, Parsian H, Vessal M, Mosapour A, Shirkhani Kelagari Z. The status of antioxidants, malondialdehyde and some trace elements in serum of patients with breast cancer. Caspian J Intern Med. 2016;7(1):31-6.
18. Maria Zowczak-Drabarczyk M, Murawa D, Kaczmarek L, Połom K, Litwiniuk M. Total antioxidant status in plasma of breast cancer patients in relation to ERβ expression. Contemp Oncol (Pozn). 2013;17(6):499-503. [DOI:10.5114/wo.2013.38782] [PMID] []
19. Gupta RK, Patel AK, Kumari R, Chugh S, Shrivastav C, Mehra S, Sharma AN. Interactions between oxidative stress, lipid profile and antioxidants in breast cancer: a case control study. Asian Pac J Cancer Prev. 2012;13(12):6295-8. [DOI:10.7314/APJCP.2012.13.12.6295] [PMID]
20. Postovit L, Widmann C, Huang P, Gibson SB. Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy. Oxid Med Cell Longev. 2018;2018:6135739. [DOI:10.1155/2018/6135739] [PMID] []
21. Mobley JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 2004;25(1):3-9. [DOI:10.1093/carcin/bgg175] [PMID]
22. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents--DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000;(27):75-93. [DOI:10.1093/oxfordjournals.jncimonographs.a024247] [PMID]
23. Didžiapetrienė J, Kazbarienė B, Tikuišis R, Dulskas A, Dabkevičienė D, Lukosevičienė V, et al. Oxidant/Antioxidant Status of Breast Cancer Patients in Pre- and Post-Operative Periods. Medicina (Kaunas). 2020;56(2):70. [DOI:10.3390/medicina56020070] [PMID] []
24. Wonisch W, Falk A, Sundl I, Winklhofer-Roob BM, Lindschinger M. Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male. 2012;15(3):159-65. [DOI:10.3109/13685538.2012.669436] [PMID]
25. Hewala TI, Elsoud M. The clinical significance of serum oxidative stress biomarkers in breast cancer females. Med Res J. 2019;4(1):1-7. [DOI:10.5603/MRJ.a2018.0039]
26. Badid N, Baba Ahmed FZ, Merzouk H, Belbraouet S, Mokhtari N, Merzouk SA, et al. Oxidant/Antioxidant Status, Lipids and Hormonal Profile in Overweight Women with Breast Cancer. Pathol Oncol Res. 2010;16(2):159-67. [DOI:10.1007/s12253-009-9199-0] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb